S1PR1 and multiple sclerosis: Lower seroconversion rates were observed in multiple sclerosis patients receiving anti-CD20 or sphingosine 1-phosphate receptor modulators who were given the Pfizer, Moderna, or AstraZeneca vaccines compared with other disease-modifying therapies or untreated patients [66].